Hiv cure news november 2018
Here are some notable HIV cure-related news stories from November 2018:
- Breakthrough in HIV cure research: Scientists at the University of California, San Francisco (UCSF) announced a major breakthrough in HIV cure research, using a combination of antiretroviral therapy (ART) and a gene editing tool called CRISPR to eliminate HIV from infected cells. The study was published in the journal Nature Medicine. (Source: UCSF News Center, November 14, 2018)
- HIV cure trial begins in the US: The National Institutes of Health (NIH) launched a clinical trial to test a potential HIV cure, known as the "HIV Cure Strategies" trial. The trial aims to evaluate the safety and efficacy of a combination of ART and a gene editing tool called zinc finger nucleases (ZFNs) in suppressing HIV replication and eliminating the virus from infected cells. (Source: NIH News, November 15, 2018)
- New HIV cure strategy shows promise: Researchers at the University of Pennsylvania reported promising results from a new HIV cure strategy, which involves using a combination of ART and a molecule called lenalidomide to stimulate the immune system to attack and eliminate HIV-infected cells. The study was published in the journal Science Translational Medicine. (Source: University of Pennsylvania News, November 20, 2018)
- HIV cure research receives funding boost: The Bill and Melinda Gates Foundation announced a $10 million grant to support HIV cure research, with a focus on developing new treatments and strategies to eliminate the virus from infected cells. The grant will support research at institutions including the University of California, San Francisco, and the University of Pennsylvania. (Source: Bill and Melinda Gates Foundation News, November 27, 2018)
These are just a few examples of the HIV cure-related news stories from November 2018. While there is still no cure for HIV, ongoing research and advancements in the field offer hope for the development of effective treatments and strategies to eliminate the virus in the future.